Holen Sie sich die Stockscreener-App
2.67
1.91%
0.05
Schlusskurs vom Vortag:
$2.62
Offen:
$2.62
24-Stunden-Volumen:
859.70K
Relative Volume:
1.26
Marktkapitalisierung:
$215.13M
Einnahmen:
$52.74M
Nettoeinkommen (Verlust:
$-6.60M
KGV:
-31.60
EPS:
-0.0845
Netto-Cashflow:
$-13.63M
1W Leistung:
+5.12%
1M Leistung:
+12.66%
6M Leistung:
-5.65%
1J Leistung:
+67.92%
1-Tages-Spanne:
$2.615
$2.68
1-Wochen-Bereich:
$2.525
$2.68
52-Wochen-Spanne:
$1.5201
$3.19
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Firmenname
Protalix BioTherapeutics Inc.
Sektor
Branche
Telefon
972 4 988 9488
Adresse
2 Snunit Street, Science Park PO Box 455, Karmiel
Compare PLX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
2.67 | 191.76M | 52.74M | -6.60M | -13.63M | -0.0845 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-17 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-04-04 | Eingeleitet | Rodman & Renshaw | Buy |
| 2015-04-23 | Hochstufung | Jefferies | Hold → Buy |
| 2014-11-12 | Bestätigt | R. F. Lafferty | Buy |
| 2014-01-24 | Eingeleitet | R. F. Lafferty | Buy |
| 2012-05-02 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-04-30 | Herabstufung | Auriga | Buy → Hold |
| 2011-10-13 | Eingeleitet | Morgan Joseph | Hold |
| 2011-03-17 | Herabstufung | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | Bestätigt | Oppenheimer | Outperform |
| 2010-10-14 | Bestätigt | UBS | Buy |
| 2009-12-02 | Bestätigt | Hapoalim | Outperform |
| 2009-09-22 | Eingeleitet | Canaccord Adams | Buy |
| 2009-09-02 | Eingeleitet | Hapoalim | Outperform |
| 2008-12-01 | Bestätigt | Oppenheimer | Outperform |
| 2008-03-11 | Eingeleitet | UBS | Buy |
| 2007-11-20 | Eingeleitet | CIBC Wrld Mkts | Sector Outperform |
Alle ansehen
Protalix BioTherapeutics Inc. Aktie (PLX) Neueste Nachrichten
Zacks Research Issues Pessimistic Outlook for PLX Earnings - MarketBeat
Protalix (PLX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Protalix (PLX) Q2 2026 Earnings Call Transcript - The Motley Fool
Protalix BioTherapeutics (NYSEAMERICAN:PLX) Advances Plant-Cell Protein Programs - Kalkine Media
Protalix BioTherapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
PLX: Elfabrio Estimates Up - Yahoo Finance
Protalix BioTherapeutics Inc (PLX) (Q2 2026) Earnings Call Highlights: Net Income Surges to $3. ... - Yahoo! Finance Canada
Protalix BioTherapeutics Inc (PLX) (Q2 2026) Earnings Call Highl - GuruFocus
Earnings call transcript: Protalix posts stronger Q2 2026 revenue, shares slip premarket - Investing.com
Protalix BioTherapeutics Inc (PLX) Reports Q2 Earnings: $19.8M R - GuruFocus
Protalix BioTherapeutics, Inc. (PLX) Q2 FY2026 earnings call transcript - Yahoo Finance
Form 8K Protalix Biotherapeutics Inc For: 12 August By Investing.com - Investing.com South Africa
Protalix BioTherapeutics reports Q2 revenue gro... - Pluang
Protalix BioTherapeutics, Inc. 2026: Revenue $19.9M, EPS $0.05— 10-Q Summary - TradingView
Protalix BioTherapeutics (PLX) swings to $22.1M H1 profit on Elfabrio milestone - Stock Titan
Protalix Posts $19.9 Million Q2 Revenue and $3.8 Million Net Income - Quiver Quantitative
Protalix BioTherapeutics reports $53.6M YTD revenue, $22.1M net income in H1 2026 - TradingView
Protalix: Q2 Earnings Snapshot - 10TV
Protalix BioTherapeutics, Inc. Reaffirms Earnings Guidance for the Year 2026 - marketscreener.com
Protalix swings to Q2 profit of USD 3.8 million; revenue from selling goods rises 28.5% to USD 19.8 million - Bitget
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026 - PR Newswire
Protalix BioTherapeutics (PLX) Slips 1% as Shares Hover Between Support and ResistanceInitial Balance - Vinanet
Protalix BioTherapeutics, Inc. Share Price Live Today – AMEX:PLX Stock Price, Chart, News, History - Upstox
Earnings Preview: PLX to Report Financial Results Pre-market on August 12 - Moomoo
Protalix will webcast its business update at 8 a.m. Aug. 12 - Stock Titan
Protalix BioTherapeutics (PLX) Edges Higher Amid Consolidation Near SupportSupport Level Bounce - dars.gov.et
BlackRock (NYSE: BLK) discloses 5.02% ownership in Protalix BioTherapeutics (PLX) - Stock Titan
Protalix Biotherapeutics Inc (PLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Price to earnings forward of Protalix Biotherapeutics, Inc. – MUN:PBDA - TradingView
Protalix Biotherapeutics Inc (PLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Protalix Biotherapeutics Inc (PLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PLX|Protalix Biotherapeutics Inc|Price:2.370|Chg%:+0.110 - TradingKey
PLX|Protalix Biotherapeutics Inc|Price:2.440|Chg%:+0.070 - TradingKey
Protalix Biotherapeutics Inc (PLX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Protalix Biotherapeutics Inc (PLX) Institutional Confidence - TradingKey
Protalix Biotherapeutics Inc (PLX) Cash Flow - TradingKey
Protalix Biotherapeutics Inc (PLX) Earnings Date & Reports & Earnings News - TradingKey
Protalix BioTherapeutics Market Sentiment - Benzinga España
PLX|Protalix Biotherapeutics Inc|Price:2.220|Chg%:-0.145 - TradingKey
Protalix Biotherapeutics Inc (PLX) Balance Sheet - TradingKey
Protalix Biotherapeutics Inc (PLX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Protalix Biotherapeutics Inc (PLX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Protalix Biotherapeutics, Inc. Revenue Breakdown – FWB:PBDA - TradingView
Protalix BioTherapeutics (PLX) Holds Steady at $2.37 — Key Levels to WatchHedge Fund Exposure - dars.gov.et
Protalix BioTherapeutics Holds Steady at $2.37 as Key Levels Remain in FocusStop Hunt - vinanet.vn
ETFs Investing in Protalix Biotherapeutics, Inc. Stocks - TradingView
PLXProtalix BioTherapeutics Inc Volatility & Greeks - Finviz
Price to book forward of Protalix Biotherapeutics, Inc. – SWB:PBDA - TradingView
PLX Q1 2026 Earnings: Stunning EPS Surprise Driven by Operational StrengthsCEO Earnings Statement - dars.gov.et
Price to sales forward of Protalix BioTherapeutics, Inc. (DE) – AMEX:PLX - TradingView
Price to sales forward of Protalix Biotherapeutics, Inc. – SWB:PBDA - TradingView
Finanzdaten der Protalix BioTherapeutics Inc.-Aktie (PLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Protalix BioTherapeutics Inc.-Aktie (PLX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bar-Shalev Amos | Director |
Nov 18 '25 |
Sale |
1.87 |
168 |
314 |
0 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):